T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
The sequence of cytoreductive nephrectomy: glass half empty or glass half full?
Axel Bex,Thomas Powles +1 more
TL;DR: It is the feeling that the CARMENA and SURTIME study ask different questions and together can address the question of targeted therapy and nephrectomy once and for all.
Proceedings ArticleDOI
Abstract 2979: A balance of genomic instability, tumor-immune contexture and TGF-β signaling contributing to exclusion of T cells governs response to PD-L1 checkpoint blockade
Sanjeev Mariathasan,Shannon J. Turley,Dorothee Nickles,Alessandra Castiglioni,Kobe C. Yuen,Yulei Wang,Edward E. Kadel,Hartmut Koeppen,Jillian L. Astarita,Rafael Cubas,Suchit Jhunjhunwala,Yagai Yang,Yasin Senbabaoglu,Ira Mellman,Daniel S. Chen,Priti S. Hegde,Richard Bourgon,Thomas Powles +17 more
TL;DR: Pre-existing T-cell immunity and TMB are associated with response to atezolizumab in mUC, whereas TGF-β signaling in the stroma is a negative indicator of response, especially in immune-excluded tumors, a common phenotype of mUC.
Journal ArticleDOI
Cabozantinib (C) exposure-response (ER) modeling of safety endpoints in patients (pts) with renal cell carcinoma (RCC) in the phase III METEOR study.
Steven Lacy,Matthew M. Hutmacher,Bei Yang,Robert J. Motzer,Bernard Escudier,Thomas Powles,Toni K. Choueiri,Jace Nielsen +7 more
TL;DR: Time-to-event Cox proportional hazard ER models showed that C would be effective at the 60 mg starting dose evaluated in METEOR as well as dose levels of 40 and 20 mg resulting from dose reduction resulting fromdose reduction.
Journal ArticleDOI
PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC).
Robert Huddart,Arlene O. Siefker-Radtke,Arjun Vasant Balar,Mehmet Asim Bilen,Thomas Powles,Aristotelis Bamias,Daniel Castellano,Maged F. Khalil,Michiel S. van der Heijden,Vadim S. Koshkin,David Pook,Mustafa Ozguroglu,Linda Santiago,Rabih Saab,Pao-Chen Li,Margit Cecile Tagliaferri,Wei Lin,Mary Tagliaferri,Yohann Loriot +18 more
TL;DR: It is shown that checkpoint inhibitors can achieve durable responses in cis-ineligible 1L mUC and use is restricted to patients whose tumors are PD-L1 high.